Download PDF
Thromb Haemost 1994; 71(05): 670-674
DOI: 10.1055/s-0038-1642501
Review Article
Schattauer GmbH Stuttgart

Effect of Human IgG Antiphospholipid Antibodies on an In Vivo Thrombosis Model in Mice

Silvia S Pierangeli
1   The Division of Rheumatology, Department of Medicine, University of Louisville, Louisville, KY, USA
,
John H Barker
2   The Division of Plastic Surgery, Department of Surgery, University of Louisville, Louisville, KY, USA
,
Dejzi Stikovac
1   The Division of Rheumatology, Department of Medicine, University of Louisville, Louisville, KY, USA
,
Douglas Ackerman
3   The Department of Pathology, Alliant Health System, Norton and Kosair’s Children Hospital, Louisville, KY, USA
,
Gary Anderson
4   The Department of Physiology, University of Louisville, Louisville, KY, USA
,
Jordi Barquinero
1   The Division of Rheumatology, Department of Medicine, University of Louisville, Louisville, KY, USA
,
Robert Acland
2   The Division of Plastic Surgery, Department of Surgery, University of Louisville, Louisville, KY, USA
,
E Nigel Harris
1   The Division of Rheumatology, Department of Medicine, University of Louisville, Louisville, KY, USA
› Author Affiliations
Further Information

Publication History

Received 17 August 1993

Accepted after resubmission 25 January 1994

Publication Date:
06 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

High levels of IgG antiphospholipid antibodies (aPL) have been associated with clinical thrombosis. It is uncertain however whether these antibodies play a direct role in thrombosis or are merely epiphenomena. To investigate whether antiphospholipid antibodies might play a role in thrombosis, we utilized a novel mouse model in which the dynamics of in vivo thrombosis can be studied. CD1 mice (26-30 g) were passively immunized with 25 mg of human IgG from a patient with the Antiphospholipid Syndrome (IgG-APS) (n = 17), IgG from normal pooled sera (TgG-NHS) (n = 9). or saline solution (n = 17), followed by 40 mg of the same preparations at 48 h. At 72 h, levels of human aPL antibodies, detected using the anticardiolipin ELISA test (aCL ELISA test), in mice immunized with IgG-APS, were 50-100 GPL units. Each animal was anesthetized, femoral vein minimally mobilized and subjected to a standardized “pinch” injury to induce thrombosis. The vessel was transilluminated using acrylic optical fibers connected to a light source, and clot formation and dissolution were visualized by a standard surgical microscope equipped with a video camera, video recorder, and computer assisted analysis system. Results showed that average clot size was significantly larger in mice immunized with IgG-APS compared to those treated with saline (p <0.037). In addition, the thrombus persisted longer in a significantly higher number of mice immunized with IgG-APS (10/17) compared to mice immunized with IgG-NHS (1/9) or saline (2/12) (p <0.02). These data suggest that IgG-APS may play a role in thrombus formation in humans. In addition, this study shows the feasibility of using this in vivo murine thrombus model for study of the effects of aPL antibodies.

 

  • References

  • 1 Harris EN. Syndrome of the Black Swan. Br J Haematol 1987; 26: 324-6
    PubMedGoogle Scholar
  • 2 Hughes GRV, Hams EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986; 13: 486-9
    PubMedGoogle Scholar
  • 3 Asherson RA. A “primary” antiphospholipid syndrome?. J Rheumatol 1988; 15: 1742-6
    PubMedGoogle Scholar
  • 4 Alarcon-Segovia D, Sanchez-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol 1989; 16: 482-8
    PubMedGoogle Scholar
  • 5 Harris EN, Chan JKH, Asherson RA, Aber VR, Gharavi AE, Hughes GRV. Thrombosis, recurrent fetal loss, thrombocytopenia: predictive value of IgG anticardiolipin antibodies. Arch Intern Med 1986; 146: 2153-9
    CrossrefPubMedGoogle Scholar
  • 6 Alving BM, Barr CF, Tang BD. Correlation between lupus anticoagulants and anticardiolipin antibodies in patients with prolonged activated partial thromboplastin times. Am J Med 1990; 88: 112-6
    CrossrefPubMedGoogle Scholar
  • 7 Lockshin MD, Druzin ML, Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynecol 1989; 160: 439-43
    CrossrefPubMedGoogle Scholar
  • 8 Loizou S, Byion MA, Englert HR, Walporl MJ, Hughes GRV. Association of quantitative anti-cardiolipin antibody levels with fetal loss. Q J Med 1988; 68: 525-31
    PubMedGoogle Scholar
  • 9 Alarcon-Segovia D, Deleze M, Orai CV. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine 1990; 68: 353-65
    PubMedGoogle Scholar
  • 10 Boey ML, Calaco CB, Gharavi AE. Thrombosis in SLE: striking association with the presence of circulating “lupus anticoagulant”. Br Med J. 1983; 287: 1021-3
    PubMedGoogle Scholar
  • 11 Elias M, Eldor A. Thromboembolism in patients with the “lupus-like” circulating anticoagulant. Arch Intern Med 1984; 144: 510-5
    CrossrefPubMedGoogle Scholar
  • 12 Branch WD. Immunologic disease and fetal death. Clin Obstet Gynecology 1987; 30: 295-311
    PubMedGoogle Scholar
  • 13 Lubbe WF, Butler WS, Palmer SJ, Liggins GC. Lupus anticoagulant in pregnancy. Br J Obstet Gynaecol 1984; 91: 357-63
    CrossrefPubMedGoogle Scholar
  • 14 Branch DW, Dudley DJ, Mitchell MD, Creightari KA, Abott IM, Hammond EH, Daynes RA. Immunoglobulin G fractions from patients with antiphospholipid antibodies caused fetal death in Balb/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 1990; 163: 210-6
    CrossrefPubMedGoogle Scholar
  • 15 Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of antiphospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anticardiolipin antibodies. Proc Natl Acad Sci (USA) 1991; 88: 3069-73
    CrossrefPubMedGoogle Scholar
  • 16 Mendlovic S, Brocke S, Shoenfeld Y, Ben Bassat M, Meshorer A, Bakimer R, Mozes E. Induction of a systemic lupus erythematosus-like disease by a common human antiDNA idiotype. Proc Natl Acad Sci (USA) 1988; 85: 2260-4
    CrossrefPubMedGoogle Scholar
  • 17 Bakimer R, Fishman P, Blank M, Srednc B, Djaidetti M, Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody. J Clin Invest 1992; 89: 1558-63
    CrossrefPubMedGoogle Scholar
  • 18 Sthoeger ZM, Tartakovsky B, Bentwich Z, Mozes E. Monoclonal anticardiolipin antibodies derived from mice with experimental lupus erythematosus: characterization and the induction of a secondary antiphospholipid syndrome. I Clin Immunol 1993; 13: 127-38
    PubMedGoogle Scholar
  • 19 Fishman P, Falach-Vaknine E, Zigelman Rosa, Bakimer R, Sredni B, Djaletti M, Shoenfeld Y. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3. J Clin Invest 91: 1834-7
    PubMedGoogle Scholar
  • 20 Gharavi AE. Anti-phospholipid syndrome in murine lupus. In: Phospholipid binding antibodies. Harris EN, Exner T, Asherson RA, Hughes GRV. (eds) CRC Press; Boca Raton: 1991: 403-16
    Google Scholar
  • 21 Smith HR, Hansen CL, Rose R, Canoso RT. Autoimmune MRL-lpr/lpr mice are an animal model for the secondary antiphospholipid syndrome. J Rheumatol 1990; 17: 911-5
    PubMedGoogle Scholar
  • 22 Weir DM. (ed) Handbook of Experimental Immunology vol: I. Immunochemistry. Blackwell Sci Publ. Oxford: 1973
    Google Scholar
  • 23 Harris EN. Annotation: antiphospholipid antibodies. Br J Haematol 1990; 74: 1-9
    PubMedGoogle Scholar
  • 24 Stockmans F, Deckinyn H, Gruwez J, Vemiylen J, Aclund R. Continuous quantitative monitoring of mural thrombus kinetics in the crushed rat femoral vein. Thromb Haemost 1991; 65: 425-31
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Comp PC, De Baukt LE, Esmon NL, Esmon CT. Human thrombomodulin is inhibited by IgG from two patients with nonspecific anticoagulants (abstract). Blood 1983; 62: 299a
    PubMedGoogle Scholar
  • 26 Freyssinet JM, Wiesel ML, Gauchy J, Boneu B, Cazenave IP. An IgM lupus anticoagulant that reutilizes the enhancing effect of phospholipid on purified thrombomodulin activity. A mechanism for thrombosis. Thromb Haemost 1986; 55: 309-13
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Cariou R, Tobelin G, Bellucci S, Soria J. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells inhibition of thrombomodulin dependent protein C activation. Thromb Haemost 1988; 60: 54-8
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989; 74: 2426-32
    PubMedGoogle Scholar
  • 29 Brandt JT. Assays for phospholipid-dependent formation of thrombin and Xa: a potential method for quantifying lupus anticoagulant activity. Thromb Haemost 1991; 66: 453-8
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Galli M, Beguin S, Lindhout T, Hemker CH. Inhibition of phospholipid and platelet dependent prothrombinase activity in the plasma of patients with lupus anticoagulants. Am J Haematol 1989; 72: 549-55
    CrossrefPubMedGoogle Scholar
  • 31 Galli M, Comfurius P. Maasen et al Anticardiolipin antibodies directed not to cardiolipin but to a plasma protein co-factor. Lancet 1990; 336: 1547-50
    CrossrefPubMedGoogle Scholar
  • 32 Mc Neil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipidbinding inhibitor of coagulation: β2 glycoprotein 1 (apolipoprotein H). Proc Natl Acad Sci (USA) 1990; 87: 4120-4
    CrossrefPubMedGoogle Scholar